Richard Morter

Oxford, ENG OX37DQ, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Phase I/IIa study to assess the safety, immunogenicity and efficacy of ChAdOx1-MVA vectored vaccines expressing a novel liver-stage malaria dual antigen LS2 by sporozoite challenge in malaria-naïve adults.

Phase I/IIa study to assess the safety, immunogenicity and efficacy of ChAdOx1-MVA vectored vaccines expressing a novel liver-stage malaria dual antigen LS2 by sporozoite challenge in malaria-naïve adults.

Journal: Wellcome open research

Published: March 19, 2026

Baseline Treg frequency, Treg-associated immune checkpoint responses, and plasma IL-10 responses during controlled human malaria infection in semi-immune Kenyan adults: a secondary analysis of the CHMI-SIKA Study.

Baseline Treg frequency, Treg-associated immune checkpoint responses, and plasma IL-10 responses during controlled human malaria infection in semi-immune Kenyan adults: a secondary analysis of the CHMI-SIKA Study.

Journal: The Lancet. Microbe

Published: April 22, 2025

Looped quality improvement project of consent forms in patients admitted with hip fracture.

Looped quality improvement project of consent forms in patients admitted with hip fracture.

Journal: Journal of clinical orthopaedics and trauma

Published: October 29, 2024

R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection study.

R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection study.

Journal: The Lancet. Microbe

Published: October 05, 2023

Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials.

Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials.

Journal: The Lancet. Microbe

Published: October 05, 2023

Impact of exposure to malaria and nutritional status on responses to the experimental malaria vaccine ChAd63 MVA ME-TRAP in 5-17 month-old children in Burkina Faso.

Impact of exposure to malaria and nutritional status on responses to the experimental malaria vaccine ChAd63 MVA ME-TRAP in 5-17 month-old children in Burkina Faso.

Journal: Frontiers in immunology

Published: September 30, 2022

Deep Immune Phenotyping and Single-Cell Transcriptomics Allow Identification of Circulating TRM-Like Cells Which Correlate With Liver-Stage Immunity and Vaccine-Induced Protection From Malaria.

Deep Immune Phenotyping and Single-Cell Transcriptomics Allow Identification of Circulating TRM-Like Cells Which Correlate With Liver-Stage Immunity and Vaccine-Induced Protection From Malaria.

Journal: Frontiers in immunology

Published: October 15, 2021

Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.

Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.

Journal: Nature medicine

Published: May 22, 2021

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.

Journal: Nature medicine

Published: October 28, 2020

Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal.

Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal.

Journal: The Journal of infectious diseases

Published: July 02, 2018

Activation-induced Markers Detect Vaccine-Specific CD4⁺ T Cell Responses Not Measured by Assays Conventionally Used in Clinical Trials.

Activation-induced Markers Detect Vaccine-Specific CD4⁺ T Cell Responses Not Measured by Assays Conventionally Used in Clinical Trials.

Journal: Vaccines

Published: June 25, 2018

Examining human paragonimiasis as a differential diagnosis to tuberculosis in The Gambia.

Examining human paragonimiasis as a differential diagnosis to tuberculosis in The Gambia.

Journal: BMC research notes

Published: September 11, 2017

Showing 1-12 of 13

Last Updated: 09/26/2026